High-dimensional immune profiling
Publications from a variety of academic and industry groups, including work co-authored by Teiko scientists, demonstrate the critical role of high-dimensional immune profiling in therapeutic development
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Drs. Kovacsovics-Bankowski & Sweere use Teiko’s mass cytometry capabilities to profile blood immune cells from melanoma patients and identify biomarkers associated with severe immune-related adverse events.
Peripheral immune features associated with severe immune-related adverse events and clinical benefit in checkpoint inhibitor-treated melanoma
Drs. Kovacsovics-Bankowski (Huntsman Cancer Institute) & Sweere (Teiko Bio) presented at SMR 2023 on peripheral immune features associated with severe immune-related adverse events and clinical benefit in melanoma patients treated with checkpoint inhibitor.
Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa in patients with advanced non-small cell lung cancer
In this abstract published as part of ASCO 2023, McAdams & Medina et al. present data on immune signatures of clinical activity in patients with advanced NSCLC treated with bintrafusp alfa, a bifunctional anti-PDL1 / TGF-beta trap.
Immune features associated with clinical benefit and adverse events in response to immunotherapy in UC patients
Teiko scientists Drs. Healy & Sweere presented at AACR 2023 on immune features of immune-related adverse events and anti-PD1 response in blood in patients with urothelial carcinoma. These data were generated through a collaboration between the Parker Institute for Cancer Immunotherapy and Teiko Bio.
Peripheral immune features associated with severe adverse events in melanoma
Drs. Healy (Teiko Bio) & Kovacsovics-Bankowski (Huntsman Cancer Institute) presented at SITC 2022 on immune signatures of severe immune-related adverse events in blood in patients with advanced melanoma treated with immunotherapy. This data was generated through a collaboration between Dr. Siwen Hu-Lieskovan of the Huntsman Cancer Institute and Teiko Bio.
Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients
Burnett, Okholm, & Tenvooren, et al. use immune profiling by mass cytometry to identify an immune trajectory associated with COVID recovery and immune subsets associated with a requirement for mechanical ventilation
Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response
Levine & Hiam-Galvez et al. use mass cytometry to profile metabolic states of early-activated CD8 T cells during infection and non-Hodkins lymphoma.
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen & Hiam et al. use mass cytometry to define changes in immune cell frequencies and states across five tissue types in eight different mouse tumor models.
Comprehensive immune monitoring of clinical trials to advance human immunotherapy
Hartmann et al. describes the development and utilization of a comprehensive and easily customizable 33-marker mass cytometry panel optimized for immune monitoring of clinical trials.
Systemic immunity Is required for effective cancer immunotherapy
In this seminal Cell 2017 publication, Spitzer, Carmi & Reticker-Flynn et al. show that effective immunotherapy treatment requires peripheral immune cell engagement in both breast and colon cancer mouse models.
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Rahim, Okholm, & Jones et al. show that immune checkpoint blockade activates CD8 T cell differentiation and proliferation in the lymph node, not within the tumor microenvironment, and these cells can be detected in transit via blood profiling.